Inhibition of AKT/FoxO3a signaling induced PUMA expression in response to p53-independent cytotoxic effects of H1: A derivative of tetrandrine

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9
   PubMed Web of Science ®Google Scholar
• Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001; 85:1813–23; PMID:11747320; http://dx.doi.org/10.1054/bjoc.2001.2128
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307–10; PMID:11099028; http://dx.doi.org/10.1038/35042675
   PubMed Web of Science ®Google Scholar
• Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206–8; PMID:7477327; http://dx.doi.org/10.1038/378206a0
   PubMed Web of Science ®Google Scholar
• Matijasevic Z, Steinman HA, Hoover K, Jones SN. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice. Mol Cell Biol 2008; 28:1265–73; PMID:18039860; http://dx.doi.org/10.1128/MCB.01108-07
   PubMed Web of Science ®Google Scholar
• Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29:684–8; PMID:11709054; http://dx.doi.org/10.1042/BST0290684
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594–604; PMID:12154352; http://dx.doi.org/10.1038/nrc864
   PubMed Web of Science ®Google Scholar
• Gottlieb TM, Leal JFM, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002; 21:1299–303; PMID:11850850; http://dx.doi.org/10.1038/sj.onc.1205181
   PubMed Web of Science ®Google Scholar
• Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13:217–36; PMID:24577402; http://dx.doi.org/10.1038/nrd4288
   PubMed Web of Science ®Google Scholar
• Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493:542–6; PMID:23242140; http://dx.doi.org/10.1038/nature11743
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27 Suppl 1:S71–83; http://dx.doi.org/10.1038/onc.2009.45
   PubMedGoogle Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683–94; PMID:11463392; http://dx.doi.org/10.1016/S1097-2765(01)00214-3
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673–82; PMID:11463391; http://dx.doi.org/10.1016/S1097-2765(01)00213-1
   PubMed Web of Science ®Google Scholar
• Ming L, Sakaida T, Yue W, Jha A, Zhang L, Yu J. Sp1 and p73 activate PUMA following serum starvation. Carcinogenesis 2008; 29:1878–84; PMID:18579560; http://dx.doi.org/10.1093/carcin/bgn150
   PubMed Web of Science ®Google Scholar
• Dudgeon C, Wang P, Sun X, Peng R, Sun Q, Yu J, Zhang L. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol Cancer Ther 2010; 9:2893–902; PMID:20978166; http://dx.doi.org/10.1158/1535-7163.MCT-10-0635
   PubMed Web of Science ®Google Scholar
• Wang P, Qiu W, Dudgeon C, Liu H, Huang C, Zambetti GP, Yu J, Zhang L. PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ 2009; 16:1192–202; PMID:19444283; http://dx.doi.org/10.1038/cdd.2009.51
   PubMed Web of Science ®Google Scholar
• Wei N, Sun H, Wang FP, Liu GT. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemoth Pharm 2011; 67:1017–25; http://dx.doi.org/10.1007/s00280-010-1397-7
   PubMed Web of Science ®Google Scholar
• Wei N, Liu GT, Chen XG, Liu Q, Wang FP, Sun H. H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochem Pharmacol 2011; 82:1593–603; PMID:21864508; http://dx.doi.org/10.1016/j.bcp.2011.08.012
   PubMed Web of Science ®Google Scholar
• Parrish AB, Freel CD, Kornbluth S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol 2013; 5; pii: a008672; PMID:23732469; http://dx.doi.org/10.1101/cshperspect.a008672
   PubMed Web of Science ®Google Scholar
• Jeffers JR, Parganas E, Lee Y, Yang CY, Wang JL, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4:321–8; PMID:14585359; http://dx.doi.org/10.1016/S1535-6108(03)00244-7
   PubMed Web of Science ®Google Scholar
• Vela L, Gonzalo O, Naval J, Marzo I. Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation. J Biol Chem 2013; 288:4935–46; PMID:23283967; http://dx.doi.org/10.1074/jbc.M112.422204
   PubMed Web of Science ®Google Scholar
• You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A, Mak TW. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203:1657–63; PMID:16801400; http://dx.doi.org/10.1084/jem.20060353
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen JC, Tseng SH. Effects of tetrandrine plus radiation on neuroblastoma cells. Anticancer Res 2009; 29:3163–71; PMID:19661330
   PubMed Web of Science ®Google Scholar
• Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002; 38:418–26; PMID:11818209; http://dx.doi.org/10.1016/S0959-8049(01)00356-2
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang J, Ying C, Wang Q, Yan C, Jingyue Y, Zhaocai Y, Yan X, Heng-Jun S, Lin J. Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy. Int J Biomed Sci 2012; 8:28–35; PMID:23675254
   PubMedGoogle Scholar
• Oh SH, Lee BH. Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem Pharmacol 2003; 66:725–31; PMID:12948852; http://dx.doi.org/10.1016/S0006-2952(03)00397-6
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003; 100:1931–6; PMID:12574499; http://dx.doi.org/10.1073/pnas.2627984100
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Cusack JC, Jr. Targeting the NF-kappaB pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22:705–46; PMID:24012396; http://dx.doi.org/10.1016/j.soc.2013.06.011
   PubMed Web of Science ®Google Scholar
• Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010; 1805:167–80; PMID:20079806
   PubMed Web of Science ®Google Scholar
• Sun J, Sun Q, Brown MF, Dudgeon C, Chandler J, Xu X, Shu Y, Zhang L, Yu J. The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. PloS One 2012; 7:e43158; PMID:22912816; http://dx.doi.org/10.1371/journal.pone.0043158
   PubMedGoogle Scholar
• Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C, Wei Y. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 2012; 444:291–301; PMID:22394200; http://dx.doi.org/10.1042/BJ20111855
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497–501; PMID:9822382; http://dx.doi.org/10.1126/science.282.5393.1497
   PubMed Web of Science ®Google Scholar
• Wei N, Chu E, Wu SY, Wipf P, Schmitz JC. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells. Oncotarget 2015; 6:4745-56.PMID: 25544765
   Google Scholar
• Wei N, Chu E, Wipf P, Schmitz JC. Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther 2014; 13:1130–41; PMID:24634417; http://dx.doi.org/10.1158/1535-7163.MCT-13-0880
   PubMed Web of Science ®Google Scholar